Continuing Education

This activity is designed for physicians, nurses, and certified tumor registrars.  Upon completion of this conference, they will be able to:

• Review the goal for changing the NAPBC standards to reflect the patient journey.
• Discuss the requirements for the new NAPBC accreditation standards, Optimal Resources for Breast Care, and how they apply to their accredited center.
• Describe the implementation plan for the standards and design a strategy for their accredited center.
• Evaluate the work to date of the PROMPT study and prepare for future QI studies released by the NAPBC.

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and authors) has disclosed all financial relationships with any companies defined as “ineligible” by the ACCME:

• Ineligible Company: Defined by the ACCME as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.
• Financial Relationships: Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
• Conflict of Interest: Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.

Jill Dietz, MD, MHCM, FACS - Peace Medical Consulting LLC, Director/Moderated for TransAtlantic breast Cancer collaborative Conference, November, 2022, received fee

Denise M. Mammolito, MD, FACS - (Nothing to disclose)

Katharine Yao, MD, FACS - (Nothing to disclose)

Richard J. Bleicher, MD, FACS - Elucent Medical, Consultant/Speaker, received honorarium

Toan T. Nguyen, MD, FACS - Aptitude Health, Consultant, received fee

Richard Reitherman, MD, PhD - (Nothing to disclose)

Randy Stevens, MD - (Nothing to disclose)

Lee Gravatt Wilke, MD, FACS - Elucent Medical, Company founder, minority stock owner; Perimeter, PI of Clinical trial, Institutional Support for Clinical Trial

Paul Jeffers - (Nothing to disclose)

Judy Boughey, MBBCh, FACS -  Peerview, Speaker, received honorarium

Virginia Schaffer, MD, FACS - (Nothing to disclose)

Kimberly Yee, MD, FACS - (Nothing to disclose)

Mediget Teshome, MD, FACS - Endonaf, Conference attendance, received travel/accommodation

Timothy Vreeland, MD, FACS - LumaBridge, Designed clinical trial, received consulting fee

Rebecca Snyder, MD, FACS - (Nothing to disclose)

Alexander Olawaiye, MD, FACS - AstraZeneca, GSK, Clovis Scientific Advisory Board Meeting, received honorarium

Thomas Baker, MD - (Nothing to disclose)

Laurie Kirstein, MD, FACS - (Nothing to disclose)

Bruce Brenner, MD, FACS - (Nothing to disclose)

Mehra Golshan, MD, FACS - Bertis, Scientific Advisor, received honorarium

Denise Mammolito, MD, FACS - (Nothing to disclose)

M. Asa Carter - (Nothing to disclose)

Chantel Ellis - (Nothing to disclose)

Alexander Barton - (Nothing to disclose)

Amanda Francescatti - (Nothing to disclose)

Eileen Riley - (Nothing to disclose)

Clarissa Orr - (Nothing to disclose)

Judy Boughey, MBBCh, FACS - Peerview, speaker, honorarium

Virginia Shaffer, MD, FACS - (Nothing to disclose)

Kimberly Yee, MD, FACS - (Nothing to disclose)

Mediget Teshome, MD, FACS - Endonaf travel, attendee, accommodation

Timothy Vreeland, MD, FACS - LumaBridge, designing clinical trial, consulting fee

This activity is designed for physicians, nurses, and certified tumor registrars. Upon completion of this course attendees will be able to:

• Discuss the updates and changes to the accreditation standards and methods for success at the site visit.
• Describe the basic elements of a QI project and illustrate how this can be applied to evaluating and improving cancer care.
• Apply basic cancer staging criteria and the new cancer schema to correctly classify cancer stage.
• Create a plan for the implementation of new operative standards and reporting of synoptic information.

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as “ineligible companies”, defined below) held in the last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.

• Ineligible Company: The ACCME defines an “ineligible company” as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.
• Financial Relationships: Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
• Conflict of Interest: Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.

Katherine Yao, MD, FACS - (Nothing to disclose)

Kathryn Schmitz, PhD, MPH - (Nothing to disclose)

Toan T. Nguyen, MD, FACS - Aptitude Consultant Fee

Richard Reitherman, MD, PhD - (Nothing to disclose)

Randy Stevens, MD - (Nothing to disclose)

Jane Meisel, MD - AstraZeneca, Clovis, Genentech, GlaxoSmithKline, Novartis, Pfizer, Puma, Sanofi Genzyme, Seagen, Seagen, Pfizer, Olema; PI on trials, received research funding (to institution)

Paul Jeffers -(Nothing to disclose)

Richard Bleicher, MD, FACS - Elucent Medical, Consultant/ Speaker, received honorarium

Lee Gravatt Wilke, MD, FACS - Elucent Medical, Company Founder, minority stock owner; Perimeter, PI of Clinical trial, Institutional support for clinical trial

Paul Baron, MD, FACS - (Nothing to disclose)

Arif Kamal, MD, MBA, MHS, FACP, FAAHPM, FASCO - (Nothing to disclose)

Sharon Lum, MD, MBA, FACS - (Nothing to disclose)

Daniel Boffa, MD, FACS - Lovance, Attended a panel discussion May 2022, received honorarium

Ryan McCabe, PhD - (Nothing to disclose)

Anthony D Yang, MD, MS, FACS - (Nothing to disclose)

Laurie J. Kirstein, MD, FACS - (Nothing to disclose)

Eileen Reilly, MSW - (Nothing to disclose)

Elizabeth Wick, MD, FACS - (Nothing to disclose)

Timothy Vreeland, MD, FACS - LumaBridge, Consultant, received consulting fee

Ryan Merkow, MD, MS - (Nothing to disclose)

Sara Holton, CTR - (Nothing to disclose)

Arden Morris, MD, MPH, FACS - (Nothing to disclose)

Maria Castaldi, MD, FACS - (Nothing to disclose)

William R. Burns, MD, FACS - (Nothing to disclose)

Kimberly Yee, MD, FACS, FASCRS - (Nothing to disclose)

David Dietz, MD, FACS - (Nothing to disclose)

Jill Dietz, MD - Peace Medical Consulting LLC, Director/Moderated for TransAtlantic Breast Cancer Collaborative Conference Nov, 2022, received fee

Linda Farkas, MD, FACS - (Nothing to disclose)

Susan Hedlund, MSW, LCSW, OSW-C - (Nothing to disclose)

Bonnie Simpson Mason, MD, FAAOS - (Nothing to disclose)

Rebecca Snyder MD, MPH, FACS, FSSO - (Nothing to disclose)

Martin Madera - (Nothing to disclose)

Donna Gress, RHIT, CTR - (Nothing to disclose)

Alexander Olawaiye, MD, FACS - AstraZeneca, GSK, Clovis; Scientific Advisory Board Meeting, received honorarium

Judy C. Boughey, MBBCh, FACS -Peerview, speaker, received honorarium

David Freyer, DO, MS - (Nothing to disclose)

Joseph Cotler, PhD - (Nothing to disclose)

Mediget Teshome, MD, MPH, FACS - Endonaf, travel / accommodation, conference attendee

Erin Reuter, JD - (Nothing to disclose)

Timothy W. Mullett, MD, MBA, FACS - (Nothing to disclose)

Heidi Nelson, MD, FACS - (Nothing to disclose)

Firas Abed, MPH, RN, OCN - (Nothing to disclose)

Rida Ahmad, MBBS - (Nothing to disclose)

Carol-Ann Benn, MBBCH, FSC - (Nothing to disclose)

Laura Christopher, MD - (Nothing to disclose)

Grace Delizo-Grabe, BS - (Nothing to disclose)

Jami DeNigris, MSN, RN, OCN - (Nothing to disclose)

Assar Ratner, MD - (Nothing to disclose)

Adrianne Fisher - (Nothing to disclose)

Letekhar Khan - (Nothing to disclose)

Rishi Sawhney, MD - (Nothing to disclose)

Lindsay Grasso - (Nothing to disclose)

Lauren Janczewski, MD - (Nothing to disclose)

Amy Jeng, MD - (Nothing to disclose)

Leigh Johnson, DrPH, MPH, CTR - (Nothing to disclose)

Monica Khattak, DO - (Nothing to disclose)

Michelle Popadiuk, MBA, LPN, RHIT,CTR - (Nothing to disclose)

Samantha Reed RD, CSO, LD - (Nothing to disclose)

Elizabeth Reynolds, MD - (Nothing to disclose)

Jenny Zhou, MD - (Nothing to disclose)

Margaret Klein - (Nothing to disclose)

Julie Yen, MD - (Nothing to disclose)

Melissa Fuller, MS - (Nothing to disclose)

Jocelyn Rapelyea - Healthcare, received honorarium, peer educator for ABUS Review, Speaker Bureau

Mehra Golshan - Bertis, received honorarium, scientific advisor

Sharon Lum, MD, MBA, FACS - (Nothing to disclose)

Elizabeth Wick, MD, FACS - (Nothing to disclose)

Timothy Vreeland, MD, FACS - LumaBridge, designed clinical trial, received consultation fee

Kimberly Yee, FACS, FASCRS - (Nothing to disclose)

Susan Hedlund, MSW, LCSW, OSW-C - (Nothing to disclose)

Alexander Olawaiye, MD - AstraZeneca, GSK, Clovis Scientific Advisory Board Meeting, received honorarium

Judy C. Boughey, MD - Peerview, speaker, received honorarium

Linda Farkas, MD, FACS - (Nothing to disclose)

Heidi Nelson, MD, FACS - (Nothing to disclose)

Judy Boughey, MBBCh, FACS - Peerview, speaker, honorarium

Virginia Shaffer, MD, FACS - (Nothing to disclose)

Kimberly Yee, MD, FACS - (Nothing to disclose)

Mediget Teshome, MD, FACS - Endonaf travel, attendee, accommodation

Timothy Vreeland, MD, FACS LumaBridge, designing clinical trial, consulting fee